116 related articles for article (PubMed ID: 11701754)
1. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo.
Sidell KR; Olson SJ; Ou JJ; Zhang Y; Amarnath V; Montine TJ
J Neurochem; 2001 Nov; 79(3):510-21. PubMed ID: 11701754
[TBL] [Abstract][Full Text] [Related]
2. Dopamine thioethers in neurodegeneration.
Sidell KR; Amamath V; Montine TJ
Curr Top Med Chem; 2001 Dec; 1(6):519-27. PubMed ID: 11895128
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease.
Shen XM; Xia B; Wrona MZ; Dryhurst G
Chem Res Toxicol; 1996; 9(7):1117-26. PubMed ID: 8902266
[TBL] [Abstract][Full Text] [Related]
4. Dopamine mercapturate can augment dopaminergic neurodegeneration.
Montine TJ; Amarnath V; Picklo MJ; Sidell KR; Zhang J; Graham DG
Drug Metab Rev; 2000; 32(3-4):363-76. PubMed ID: 11139134
[TBL] [Abstract][Full Text] [Related]
5. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease.
Shen XM; Dryhurst G
Chem Res Toxicol; 1996 Jun; 9(4):751-63. PubMed ID: 8831820
[TBL] [Abstract][Full Text] [Related]
6. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity.
Shen XM; Dryhurst G
Chem Res Toxicol; 1998 Jul; 11(7):824-37. PubMed ID: 9671546
[TBL] [Abstract][Full Text] [Related]
7. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
8. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats.
Miller DW; Abercrombie ED
J Neurochem; 1999 Apr; 72(4):1516-22. PubMed ID: 10098856
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of nitric oxide on the uptake of [3H]dopamine and [3H]glutamate by striatal synaptosomes.
Lonart G; Johnson KM
J Neurochem; 1994 Dec; 63(6):2108-17. PubMed ID: 7964730
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
11. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat.
González-Hernández T; Barroso-Chinea P; Rodríguez M
Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease.
Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T
Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189
[TBL] [Abstract][Full Text] [Related]
13. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease.
Zhang F; Dryhurst G
J Med Chem; 1994 Apr; 37(8):1084-98. PubMed ID: 7909337
[TBL] [Abstract][Full Text] [Related]
14. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Serra PA; Esposito G; Enrico P; Mura MA; Migheli R; Delogu MR; Miele M; Desole MS; Grella G; Miele E
Br J Pharmacol; 2000 Jun; 130(4):937-45. PubMed ID: 10864903
[TBL] [Abstract][Full Text] [Related]
15. Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Mash DC; Kopin IJ; Sharabi Y
Parkinsonism Relat Disord; 2017 Feb; 35():88-91. PubMed ID: 28034624
[TBL] [Abstract][Full Text] [Related]
16. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
[TBL] [Abstract][Full Text] [Related]
17. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
Spencer JP; Jenner P; Daniel SE; Lees AJ; Marsden DC; Halliwell B
J Neurochem; 1998 Nov; 71(5):2112-22. PubMed ID: 9798937
[TBL] [Abstract][Full Text] [Related]
18. Pentobarbital inhibits L-DOPA-induced dopamine increases in the rat striatum: An in vivo microdialysis study.
Adachi YU; Yamada S; Satomoto M; Watanabe K; Higuchi H; Kazama T; Doi M; Sato S
Brain Res Bull; 2006 May; 69(5):593-6. PubMed ID: 16647588
[TBL] [Abstract][Full Text] [Related]
19. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Moy LY; Zeevalk GD; Sonsalla PK
J Neurochem; 2000 Apr; 74(4):1656-65. PubMed ID: 10737624
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic development of prenatal ventral mesencephalon and striatum in organotypic co-cultures.
Lyng GD; Snyder-Keller A; Seegal RF
Brain Res; 2007 Feb; 1133(1):1-9. PubMed ID: 17196555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
